Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.92)
# 3,069
Out of 4,935 analysts
116
Total ratings
30.77%
Success rate
-5.45%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.56 | +97.59% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $92.54 | +2.66% | 2 | Aug 6, 2025 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $11 | $7.21 | +52.67% | 3 | Aug 5, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $15.68 | +59.44% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $7.02 | +70.94% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $6.92 | +73.54% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $9.20 | -23.91% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.00 | +100.68% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $8.98 | +89.31% | 6 | May 14, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $4.65 | +93.55% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $24.80 | +85.48% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $2.01 | +298.01% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $13.90 | +72.66% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.21 | +230.58% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $7.37 | +22.12% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.63 | +147.93% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.25 | +394.12% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $7.42 | +115.63% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.35 | +159.26% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.64 | +289.41% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.43 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.46 | +1,784.44% | 2 | Aug 18, 2023 |
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.56
Upside: +97.59%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $92.54
Upside: +2.66%
CVRx, Inc.
Aug 5, 2025
Reiterates: Overweight
Price Target: $11
Current: $7.21
Upside: +52.67%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.68
Upside: +59.44%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $7.02
Upside: +70.94%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $6.92
Upside: +73.54%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $9.20
Upside: -23.91%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.00
Upside: +100.68%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $8.98
Upside: +89.31%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $4.65
Upside: +93.55%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $24.80
Upside: +85.48%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.01
Upside: +298.01%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $13.90
Upside: +72.66%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.21
Upside: +230.58%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $7.37
Upside: +22.12%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $3.63
Upside: +147.93%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.25
Upside: +394.12%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $7.42
Upside: +115.63%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.35
Upside: +159.26%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.64
Upside: +289.41%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.46
Upside: +1,784.44%